- Home
- CISO vs INKT Comparison
CISO vs INKT Comparison
Compare CISO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- INKT
- Stock Information
- Founded
- CISO 2015
- INKT 2017
- Country
- CISO United States
- INKT United States
- Employees
- CISO N/A
- INKT N/A
- Industry
- CISO Computer Software: Prepackaged Software
- INKT Medicinal Chemicals and Botanical Products
- Sector
- CISO Technology
- INKT Health Care
- Exchange
- CISO Nasdaq
- INKT Nasdaq
- Market Cap
- CISO 31.4M
- INKT 28.8M
- IPO Year
- CISO N/A
- INKT 2021
- Fundamental
- Price
- CISO $1.04
- INKT $41.04
- Analyst Decision
- CISO
- INKT Strong Buy
- Analyst Count
- CISO 0
- INKT 2
- Target Price
- CISO N/A
- INKT $37.50
- AVG Volume (30 Days)
- CISO 920.4K
- INKT 2.4M
- Earning Date
- CISO 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- CISO N/A
- INKT N/A
- EPS Growth
- CISO N/A
- INKT N/A
- EPS
- CISO N/A
- INKT N/A
- Revenue
- CISO $29,887,603.00
- INKT N/A
- Revenue This Year
- CISO N/A
- INKT N/A
- Revenue Next Year
- CISO N/A
- INKT N/A
- P/E Ratio
- CISO N/A
- INKT N/A
- Revenue Growth
- CISO N/A
- INKT N/A
- 52 Week Low
- CISO $0.26
- INKT $4.56
- 52 Week High
- CISO $3.84
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- CISO 46.11
- INKT 69.01
- Support Level
- CISO $1.16
- INKT $6.80
- Resistance Level
- CISO $1.24
- INKT $76.00
- Average True Range (ATR)
- CISO 0.10
- INKT 4.65
- MACD
- CISO -0.02
- INKT 4.24
- Stochastic Oscillator
- CISO 6.06
- INKT 49.48
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.